Journal Mobile Options
Table of Contents
Vol. 92, No. 1, 2002
Issue release date: September 2002

Hospitalizations for Valvular Heart Disease in Chronic Dialysis Patients in the United States

Abbott K.C. · Agodoa L.Y.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Valvular heart disease has not been studied in a national population of end stage renal disease patients. Methods: 327,993 dialysis patients in the United States Renal Data System initiated from 1 January 1992 to 30 June 1997 were analyzed in a historical cohort study of patients hospitalized for valvular heart disease (ICD9 Code 424.x, excluding endocarditis, and 394.x-397.x). Results: 2,778 dialysis patients were hospitalized for VHD (incidence rate, 3.57 per 1,000 person years), and dialysis patients had an age-adjusted incidence ratio for valvular heart disease of 5.06 (95% confidence interval, 4.00–6.42) compared to the general population in 1996. In Cox regression analysis, time to hospitalization for valvular heart disease was associated with earlier year of first dialysis, increased age, congestive heart failure and use of erythropoietin prior to dialysis, while African-American race (AHR 0.62, 0.52–0.74) was associated with decreased risk of hospitalization for valvular heart disease. Patients hospitalized for valvular heart disease had increased mortality compared to all other dialysis patients (adjusted hazard ratio by Cox regression 1.35, 95% CI, 1.25–1.46). Conclusions: Dialysis patients were at increased risk for hospitalizations for valvular heart disease compared to the general population, which substantially decreased patient survival. The reasons for the decreased risk of African-Americans on chronic dialysis for this complication should be the subject of future trials.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. London GM, Pannier B, Marchais SJ, Guerin AP: Calcification of the aortic valve in the dialyzed patient. J Am Soc Nephrol 2000;11:778–783.
  2. Madu EC, D’Cruz IA, Wall B, Mansour N, Shearin S: Transesophageal echocardiographic spectrum of calcific mitral abnormalities in patients with end-stage renal disease. Echocardiography 2000;17:29–35.

    External Resources

  3. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478–1483.
  4. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014–1021.

    External Resources

  5. Liu JY, Birkmeyer NJ, Sanders JH, Morton JR, Henriques HF, Lahey SJ, Dow RW, Maloney C, DiScipio AW, Clough R, Leavitt BJ, O’Connor GT: Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Circulation 2000;102:2973–2977.

    External Resources

  6. Rubenstein MH, Harrell LC, Sheynberg BV, Schunkert H, Bazari H, Palacios IF: Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 2000;102:2966–2972.

    External Resources

  7. Horst M, Mehlhorn U, Hoerstrup SP, Suedkamp M, de Vivie ER: Cardiac surgery in patients with end-stage renal disease: 10-year experience. Ann Thorac Surg 2000;69:96–101.
  8. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 2000;35:1226–1237.
  9. Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remedio F, Ribeiro F: Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism. Nephrol Dial Transplant 1998;13:2037–2040.
  11. Longenecker JC, Coresh J, Klag MJ, Levey AS, Martin AA, Fink NE, Powe NR: Validation of comorbid conditions on the end-stage renal disease medical evidence report: the CHOICE study: Choices for healthy outcomes in caring for ESRD. J Am Soc Nephrol 2000;11:520–529.
  12. Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, Emre S, Fishbein TM, Guy SR, Schwartz ME, Miller CM: Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation 2000;69:781–789.
  13. Fisher L, Vanbelle G: Biostatistics. New York, Wiley, 1993, p 771.
  14. Smith RL, Larsen D, Crawford MH, Shively BK: Echocardiographic predictors of survival in low gradient aortic stenosis. Am J Cardiol 2000;86:804–807, A10.
  15. Smolens IA, Pagani FD, Bolling SF: Mitral valve repair in heart failure. Eur J Heart Fail 2000;2:365–371.
  16. Astor BC, Kaczmarek RG, Hefflin B, Daley WR: Mortality after aortic valve replacement: Results from a nationally representative database. Ann Thorac Surg 2000;70:1939–1945.
  17. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer G, Baumgartner H: Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611–617.
  18. Yudd M, Llach F: Current medical management of secondary hyperparathyroidism. Am J Med Sci 2000;320:100–106.
  19. McFalls EO, Archer SL: Rapid progression of aortic stenosis and secondary hyperparathyroidism. Am Heart J 1990;120:206–208.
  20. Niederle B, Stefenelli T, Glogar D, Woloszczuk W, Roka R, Mayr H: Cardiac calcific deposits in patients with primary hyperparathyroidism: Preliminary results of a prospective echocardiographic study. Surgery 1990;108:1052–1056.

    External Resources

  21. Mazzaferro S, Coen G, Bandini S, Borgatti PP, Ciaccheri M, Diacinti D, Ferranti E, Lusenti T, Mancini G, Monducci I, et al: Role of ageing, chronic renal failure and dialysis in the calcification of mitral annulus. Nephrol Dial Transplant 1993;8:335–340.
  22. Stefenelli T, Abela C, Frank H, Koller-Strametz J, Globits S, Bergler-Klein J, Niederle B: Cardiac abnormalities in patients with primary hyperparathyroidism: Implications for follow-up. J Clin Endocrinol Metab 1997;82:106–112.
  23. Peniston RL, Swarup J, Barnwell JM, Crittenden MD: Cardiovascular surgery in blacks. Cardiovasc Clin 1991;21:321–339.
  24. Rostand SG, Sanders C, Kirk KA, Rutsky EA, Fraser RG: Myocardial calcification and cardiac dysfunction in chronic renal failure. Am J Med 1988;85:651–657.
  25. Iribarren C, Sidney S, Sternfeld B, Browner WS: Calcification of the aortic arch: Risk factors and association with coronary heart disease, stroke, and peripheral vascular disease. JAMA 2000;283:2810–2815.
  26. Gupta A, Kallenbach LR, Zasuwa G, Divine GW: Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol 2000;11:330–334.
  27. Pei YP, Greenwood CM, Chery AL, Wu GG: Racial differences in survival of patients on dialysis. Kidney Int 2000;58:1293–1299.

    External Resources

  28. Coco M, Rush H: Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000;36:1115–1121.

    External Resources

  29. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131–2138.
  30. Tsuchihashi K, Takizawa H, Torii T, Ikeda R, Nakahara N, Yuda S, Kobayashi N, Nakata T, Ura N, Shimamoto K: Hypoparathyroidism potentiates cardiovascular complications through disturbed calcium metabolism: possible risk of vitamin D(3) analog administration in dialysis patients with end-stage renal disease. Nephron 2000;84:13–20.
  31. Allison MJ, Gerszten E, Dalton HP: Valvular heart disease: pathogenesis and racial susceptibility. South Med J 1967;60:129–134.

    External Resources

  32. Szklo M, Nieto FJ: Epidemiology: Beyond the Basics. Gaithersburg, Aspen Publishers, 2000, pp 177–209.
  33. Shoji T, Emoto M, Shinohara K, Kakiya R, Tsujimoto Y, Kishimoto H, Ishimura E, Tabata T, Nishizawa Y: Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001;12:2117–2124.
  34. Podesta A, Carmagnini E, Parodi E, Dottori V, Crivellari R, Barberis L, Audo A, Lijoi A, Passerone G: Elective coronary and valve surgery without blood transfusion in patients treated with recombinant human erythropoietin (epoetin-alpha). Min Cardioangiol 2000;48:341–347.

    External Resources

  35. Lambertini D, Catalano C, Fabbian F, Bordin V, Di Landro D: Increasing erythropoietin dose overcomes inadequate erythropoietin response secondary to cardiac hemolysis. Nephron 2000;85:358–359.
  36. Kaplon RJ, Cosgrove DM 3rd, Gillinov AM, Lytle BW, Blackstone EH, Smedira NG: Cardiac valve replacement in patients on dialysis: Influence of prosthesis on survival. Ann Thorac Surg 2000;70:438–441.
  37. Cowan DN, DeFraites RF, Gray GC, Goldenbaum MB, Wishik SM: The risk of birth defects among children of Persian Gulf War veterans. N Engl J Med 1997;336:1650–1656.
  38. Cassel CK, Vladeck BC: ICD-9 code for palliative or terminal care. N Engl J Med 1996;335:1232–1234.
  39. Assaf AR, Lapane KL, McKenney JL, Carleton RA: Possible influence of the prospective payment system on the assignment of discharge diagnoses for coronary heart disease. N Engl J Med 1993;329:931–935.
  40. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD: Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989;320:904–910.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50